23-278 Phase I
A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies
Search Cancer Clinical Trials
Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
15 results
22-540 Phase II
A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube
22-192 Phase II
A Phase 1/2, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
19-477 Phase II
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
21-422 Phase II
A Phase 2 Study of acalabrutinib in combination with lisocabtagene maraleucel in relapsed/refractory aggressive B-cell lymphomas
18-604 Phase II
A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2).
20-011 Phase II
A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial To Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)
19-087 Phase I
A Phase I Clinical Trial with CAR-37 T Cells for the Treatment of Patients with Relapsed or Refractory CD37+ Hematologic Malignancies
20-518 Phase I
A Phase I Clinical Trial with TriPRIL CAR T Cells for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
22-258 Phase II
A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Allogeneic GDA-201 Natural Killer Cells in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
Showing 1 - 10 of 15 results